Targeted liposomal nano-therapy combining anthocyanin and cisplatin reduces Ehrlich ascites carcinoma burden
Awad, Mai G; Elshafiey, Sara Hatem; Ali, Ramadan A; Abd El-Monem, Dalia D; Badawy, Abdelnaser A; Al-Serwi, Rasha Hamed; El-Magd, Mohammed A; Hanafy, Nemany A N;
Abstract
Ehrlich ascites carcinoma (EAC), a rapidly growing tumor model, poses challenges in chemotherapy due to toxicity and resistance. Liposomal drug delivery improves anticancer therapy by enhancing bioavailability, targeting, and reducing systemic toxicity. Cisplatin (Cis), although effective, induces severe hepatic and renal toxicity. Anthocyanins (Ant), natural flavonoids with antioxidant and anticancer activities, can synergize with chemotherapy and reduce toxicity. This study evaluated three nano-liposomal formulations for EAC: Ant-loaded liposomes (Ant Ls), Cis-loaded liposomes (Cis Ls), and their combination (Cis + Ant Ls).
Other data
| Title | Targeted liposomal nano-therapy combining anthocyanin and cisplatin reduces Ehrlich ascites carcinoma burden | Authors | Awad, Mai G; Elshafiey, Sara Hatem ; Ali, Ramadan A; Abd El-Monem, Dalia D; Badawy, Abdelnaser A; Al-Serwi, Rasha Hamed; El-Magd, Mohammed A; Hanafy, Nemany A N | Keywords | Ehrlich ascites carcinoma;anthocyanin;cisplatin;drug delivery systems;liposome;target therapy | Issue Date | 2025 | Journal | Frontiers in Pharmacology | ISSN | 1663-9812 | DOI | 10.3389/fphar.2025.1659575 | PubMed ID | 41111505 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.